Neuraxpharm has rebranded a Spanish finished dosage form facility to mark its “full integration” within the group, as it focuses on building its profile in Europe.
Laboratorios Lesvi, a finished dosage form subsidiary of the Neuraxpharm group, has been rebranded to create Neuraxpharm Pharmaceuticals S.L., the parent company has announced.
Laboratorios Lesvi, based in Sant Joan Despí, Spain, is one of two manufacturing plants owned and operated by Neuraxpharm, and employs more than 280 people developing and manufacturing FDFs for the
Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.
One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.
An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.
